anti-osteoporosis

Syringin (eleutheroside-b) is a compound with antitumor, antiproliferative, immunomodulatory and platelet aggregation inhibiting effects.

KY-02327, a metabolically stabilized analog of KY-02061, serves as a potent inhibitor of the Dishevelled (Dvl)-CXXC5 interaction. This compound activates the Wnt/β-catenin pathway, thereby promoting osteoblast differentiation.

Anti-osteoporosis agent-11 (compound 3k) is an anti-osteoporosis compound targeting osteoclasts. It exhibits its most prominent effect by inhibiting osteoclast differentiation, with an IC50 value of 0.36 μM. Additionally, Anti-osteoporosis agent-11 suppresses osteoclast formation, bone resorption, and the expression of osteoclast-specific genes by blocking the RANKL-induced mitogen-activated protein kinase (MAPK) and NF-κB signaling pathways.

Anti-osteoporosis agent-10 is an inhibitor of osteoporosis that suppresses the formation of osteoclasts with an IC50 of 0.042 μM. It also exhibits antagonistic activity towards PPARγ, with an EC50 value of 0.75 μM.

Anti-osteoporosis agent-8 (Compound 4aa) is a RANKL inhibitor, capable of preventing RANKL-induced osteoclastogenesis and osteoclast differentiation, with an IC50 of 2.41 μM. Furthermore, Anti-osteoporosis agent-8 has been shown to mitigate bone loss in an ovariectomized (OVX) mouse model.

Anti-osteoporosis agent-12 (Compound 18) is an orally active pyrazole-fused betulinic acid derivative that exhibits strong anti-osteoporotic properties. It powerfully inhibits RANKL-induced osteoclastogenesis in RAW264.7 cells, with an IC50 of 7.96 nM. Additionally, Anti-osteoporosis agent-12 dose-dependently improves key micro-CT parameters of bone, reduces serum bone resorption marker levels (CTx), and effectively prevents bone loss induced by ovariectomy. This agent is useful for osteoporosis research.

Anti-osteoporosis agent-1 (comp 4aa) is a potent RPA (replication protein A) inhibitor with an IC50 value of 18 μM [1].

Anti-osteoporosis agent-4 (Compound 11h) suppresses the differentiation of primary osteoclasts and attenuates RANKL-induced osteoclastogenesis, effectively inhibiting osteoclast formation with an IC50 value of 358.29 nM, and impedes the activation of the PI3K/AKT and IκBα/NF-κB signaling pathways [1].

Anti-osteoporosis agent-2 (Compound 10) inhibits RANKL-induced osteoclast differentiation [1].

Compound 11, also known as Anti-osteoporosis agent-3, is a derivative of PMSA that serves as an anti-osteoporosis agent. It effectively inhibits osteoclastogenesis in vitro with an IC50 value of 322.9 nM. Additionally, this compound prevents the formation of F-action belts and bone resorption [1].

Anti-osteoporosis agent-9 (compound 5b) is an N-cyclopropyl-4-((sulfonylpiperazin-1-yl)methyl)benzamide derivative that exhibits anti-osteoclast activity.

Anti-osteoporosis agent-7 is an anti-osteoporosis agent and osteoclast formation inhibitor. It blocks osteoclast differentiation to reduce bone resorption in vitro.

ONO-5334 is a selective, orally active and potent histone K inhibitor with anti-SAR-COV-2 and anti-bone resorption activity for the study of osteoporosis.

E197 is an anti-osteoporotic compound, a Dock5 inhibitor, which can be used in the study of osteoporosis.

Zoledronic acid monohydrate (CGP 42446) is a synthetic imidazole bisphosphonate analog with anti-bone-resorption activity.

L-Arginine (L-Arg) is a substrate for endothelial nitric oxide synthase (eNOS), participating in protein synthesis, polyamine production, and cellular signaling regulation. L-Arginine is transported into vascular smooth muscle cells via the cationic amino acid transporter family and metabolized into nitric oxide, polyamines, or L-proline. L-Arginine is an effective vasodilator and can be used to induce experimental acute pancreatitis.

Zoledronic Acid (ZOL 446) is a bisphosphonate. Zoledronic Acid (ZOL 446) is used to prevent skeletal fractures in patients with cancers such as multiple myeloma and prostate cancer. It can also be used to treat hypercalcemia of malignancy and can be helpful for treating pain from bone metastases. An annual dose of Zoledronate may also prevent recurring fractures in patients with a previous hip fracture. Zoledronic Acid (ZOL 446) is a single 5 mg infusion for the treatment of Paget's disease of bone. In 2007, the FDA also approved Reclast for the treatment of postmenopausal osteoporosis.

Diphylloside A (Ikarisoside C) is a flavonoid glycoside and a prenylated flavonoid derivative that is frequently studied as an active component in traditional Chinese medicine. Diphylloside A exhibits antioxidant, anti-inflammatory, and bone metabolism-regulating activities, and has garnered significant attention in research on osteoporosis and the pharmacology of natural medicines.

Balamapimod, also known as MKI-822, is a small-molecule Ras/Raf/MEK inhibitor that directly targets deregulated MAPK signaling cascades and is being actively explored to suppress aberrant protein kinase activity implicated in oncogenic transformation, inflammatory signaling, and pathological cell proliferation, with demonstrated therapeutic relevance for stroke, osteoporosis, rheumatoid arthritis, polycystic kidney disease, colonic polyps, and other inflammation-driven disorders through pathway-level inhibition.

S24-14 serves as an effective anti-osteoporosis agent by inhibiting osteoclastogenesis, promoting osteoblast differentiation, and reducing bone resorption.

SPA0355 is a thiourea derivative with antioxidant and anti-inflammatory properties. It inhibits RANKL (receptor activator of nuclear factor κB ligand)-induced osteoclastogenesis in primary bone marrow-derived macrophages and suppresses the activation of MAPKs, Akt, and NF-κB pathways. Furthermore, SPA0355 enhances osteoblast differentiation by increasing alkaline phosphatase activity and mineralized nodule formation. It protects ovariectomized mice from bone loss by stimulating osteoblast differentiation and inhibiting osteoclast resorption, making it a potential candidate for studying postmenopausal osteoporosis.

SH543 is a potent anti-osteoporosis agent that inhibits RANKL-induced osteoclastogenesis, with an IC50 value of 3.3 nM. It directly binds to KEAP1, activating the Nrf2-HO-1 antioxidant pathway, reducing reactive oxygen species (ROS) levels, and inhibiting PI3K-AKT and MAPK signaling pathways. SH543 alleviates pathological bone loss in ovariectomized mice and is useful for osteoporosis research.

Saikosaponin A has a variety of pharmacological benefits, including antiepileptic, anti-osteoporosis, antioxidant, anti-in ammatory, immunomodulatory, and anti-bacterial activities. It can effectively attenuate neuropathic pain in CCI rats by inhibiting the activation of p38 MAPK and NF-κB signaling pathways in spinal cord. It can inhibit NMDA receptor current and persistent sodium current, and inhibit the TNF-α level, the IL-1β production, and cysteine-aspartic acid protease (caspase)-1 activity.

Baohuoside I (Icariside-II) is a component of Epimedium koreanum, exhibits anti-inflammatory activity and anti-osteoporosis activities.